Results 21 to 30 of about 29,286 (231)

Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension

Frontiers in Physiology, 2018
The multi-kinase inhibitor dasatinib is used for treatment of imatinib-resistant chronic myeloid leukemia, but is prone to induce microvascular dysfunction.
Csilla Fazakas, Csilla Fazakas, Chandran Nagaraj, Diana Zabini, Attila G. Végh, Leigh M. Marsh, Imola Wilhelm, István A. Krizbai, Horst Olschewski, Andrea Olschewski, Zoltán Bálint, Zoltán Bálint   +11 more
doaj   +1 more source

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. [PDF]

, 2023
Novel treatment strategies are needed for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in older patients.
Anna Moseley, Anjali S. Advani, Erba, Harry P, Jane L. Liesveld, George Yaghmour, Atallah, Ehab L, Richard M. Stone, O'Dwyer, Kristen M, Jeyakumar, Deepa, Moseley, Anna, Advani, Anjali S, Aaron T. Gerds, Harry P. Erba, Liesveld, Jane L, Jae Park, Megan Othus, Gerds, Aaron T, Elad Sharon, Wood, Brent L, Matthew Wieduwilt, Susan M. O'Brien, Sharon, Elad, Mark Litzow, Kristen M. O’Dwyer, Yaghmour, George, Othus, Megan, O'Brien, Susan M, Ehab L. Atallah, Wieduwilt, Matthew, Deepa Jeyakumar, Park, Jae, Stone, Richard M, Litzow, Mark, Brent L. Wood   +33 more
core   +1 more source

Retracted: Dasatinib promotes TRAIL‐mediated apoptosis by upregulating CHOP‐dependent death receptor 5 in gastric cancer

FEBS Open Bio, 2018
Dasatinib, a tyrosine kinase inhibitor, has been approved for first‐line treatment of leukemia and has also been evaluated for use in numerous other cancers. However, its role in gastric cancer (GC) remains unclear.
Xiaona Wang, Qiang Xue, Liangliang Wu, Baogui Wang, Han Liang   +4 more
doaj   +1 more source

Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

BMC Cancer, 2010
Background Recent studies have suggested that the Src inhibitor dasatinib preferentially inhibits the growth of breast cancer cells of the basal-like subtype.
Watanabe Mika, Kozuka Yuji, Moriya Takuya, Kanomata Naoki, Kurebayashi Junichi, Sonoo Hiroshi   +5 more
doaj   +1 more source

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis

Frontiers in Immunology, 2019
Rheumatoid arthritis (RA) is a multifactorial autoimmune disease that primarily manifests as persistent synovitis and progressive joint destruction.
Kai Guo, Kai Guo, Xin Bu, Chongfei Yang, Xiaorui Cao, Huan Bian, Qingsheng Zhu, Jinyu Zhu, Dawei Zhang   +8 more
doaj   +1 more source

Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma

BMC Cell Biology, 2018
Background Dasatinib (Sprycel) was developed as a tyrosine kinase inhibitor targeting Bcr-Abl and the family of Src kinases. Dasatinib is commonly used for the treatment of acute lymphoblastic and chronic myelogenous leukemia.
Josip Skoko, Jan Rožanc, Emilie M. Charles, Leonidas G. Alexopoulos, Markus Rehm   +4 more
doaj   +1 more source

Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity. [PDF]

PLoS ONE, 2014
Dasatinib is a compound developed for chronic myeloid leukemia as a multi-targeted kinase inhibitor against wild-type BCR-ABL and SRC family kinases. Valproic acid (VPA) is an anti-epileptic drug that also acts as a class I histone deacetylase inhibitor.
Sook-Kyoung Heo, Eui-Kyu Noh, Dong-Joon Yoon, Jae-Cheol Jo, Jae-Hoo Park, Hawk Kim   +5 more
doaj   +1 more source

Peptides GWN and GW protect kidney cells against Dasatinib induced mitochondrial injury in a SIRT1 dependent manner

Food Chemistry: Molecular Sciences, 2022
Dasatinib, a small-molecule drug used as a treatment for chronic myeloid leukemia induces mitochondrial damage in embryonic kidney (293 T) cells (p 
Khushwant S. Bhullar, Fatemeh Ashkar, Jianping Wu   +2 more
doaj   +1 more source

Dasatinib-induced Crohn’s-like colitis

, 2022
Dasatinib is a second-generation multityrosine kinase inhibitor used in the first-line and second-line treatment of Philadelphia chromosome-positive leukaemia.
Matteo Fassan, Luigi Caserta, Mastracci, Luca, Michela Campora, Mescoli, Claudia, Carlin, Luca, Fassan, Matteo, Caserta, Luigi, Luca Mastracci, Luca Carlin, Campora, Michela, Remo, Andrea, Federica Grillo, Andrea Remo, Claudia Mescoli, Fabrizio Mazza, Grillo, Federica, Mazza, Fabrizio   +17 more
core   +1 more source

Dasatinib induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells [PDF]

Investigative and Clinical Urology
Purpose: Bladder cancer is a common genitourinary malignant disease worldwide. Dasatinib is a small molecule inhibitor of Src family kinases. We investigated the anticancer effect and putative molecular mechanisms of dasatinib on T24 and cisplatin ...
Jin-Nyoung Ho, Seok-Soo Byun, Danhyo Kim, Hoyoung Ryu, Sangchul Lee   +4 more
doaj   +1 more source